Органосохранное лечение инвазивного рака мочевого пузыря
Диссертация
Таким образом, изучение различных сочетаний методов лечения инвазивного рака мочевого пузыря, ставящих задачу контроля над течением болезни и сохранения функционирующего органа, является актуальным. Выбор оптимальной комбинации позволит повысить эффективность лечения, и возможно, стать альтернативой удалению мочевого пузыря. Определена оптимальная последовательность этапов комбинированного… Читать ещё >
Список литературы
- Болотина Л.В., Scacel Т. Гемцитабин при местнораспространенном и/или метастатическом раке мочевого пузыря // Современная онкология 2002 -№ 2 — С.70−79
- Всемирная организация здравоохранения (ВОЗ). Лучевая терапия в лечении рака. Практическое руководство. // Chapman and Hall Medical -2000.
- Гарин A.M. Доцетаксел (Таксотер) в практике лечения злокачественных опухолей. // Москва 2003.
- Давыдов М.И., Аксель Е. М. Злокачественные новообразования в России и странах СНГ в 2000 г. // Москва 2002
- Карякин О.Б. Комбинированное лечение местнораспространенного и распространенного рака мочевого пузыря. Диссертация доктора мед. наук. //Обнинск 1996
- Коган М.И., Перепечай В. А. Современная диагностика и хирургия рака мочевого пузыря. // Ростов-на-Дону 2002.
- Матвеев Б.П. Клиническая онкоурология. // Москва 2003
- Матвеев Б.П., Фигурин K.M., Карякин О. Б. Рак мочевого пузыря. // Москва-2001
- Матвеев Б.П., Фигурин K.M., Токтомушев А. Т. Результаты органосохраняющей терапии инвазивного рака мочевого пузыря. // Урология 2002 № 3 — С.3−5.
- Ю.Матвеев Б. П., Фигурин K.M., Сорокин К. В. Гемцитабин в лечении местнораспространенного и диссеминированного рака мочевого пузыря. // Гемцитабин в клинической практике Москва — 2002 — С. 135−149
- П.Огнерубов H.A., Голдобенко Г. В., Мардынский Ю. С., ЧернышевИ.В., Карякин О. Б. Органосохраняющее лечение местнораспространенного рака мочевого пузыря. // Воронеж 1999
- Трапезников Н.Н., Поддубная И. В. Справочник по онкологии. // Москва -1996.
- Фигурин К.М. Химиотерапия рака мочевого пузыря. // Клиническая онкология 1999 — № 1 — С.24−28
- М.Ярмоненко С. П., Коноплянников А. Г., Вайнсон А. А. Клиническая радиобиология. // Москва 1992.
- Abol-Enein Н et al. Neo-adjuvant chemotherapy in the treatment of invasive transitional bladder cancer. A controlled prospective randomised study. // Br J Urol 1997 — 79(suppl 4) — P. 174
- Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. // The Lancet -2003 V.361 — P. 1927−34
- Angulo CJ et al. Sistemic chemotherapy with cisplatin, methotrexate, and vinblastin, and bladder preservation in T2/T3A bladder cancer. // Actas Urol Esp 1997 — V.21 -N.l — P.28−33
- Arias F et al. Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program. // Int J Rad Oncol Biol Phis 2000 — V.47 — N2 — P.373−378
- Bamias A et al. Neoadjuvant chemotherapy with Docetaxel and Cisplatin in patients with high-risk resectable bladder carcinoma: long term results. // Eur Urol 2004 — V.46 — N.3 — P.344−51
- Bassi P et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. // J Urol 1999 — V.161 -N.5-P. 1494−7
- Bassi P et al. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: results of a multicenter phase 111 trial.//J Urol 1999 -V.161 -264A
- Cervek J et al. Invasive bladder cancer: our experience with bladder sparing approach. // Int J Rad Oncol Biol Phis 1998 — V.41 — N.2 — P.273−278
- Clarke GM, Cooke D. A basic course in statistics. // London: Edward Arnold -1978.
- Colvett KT et al. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer. // J Surg Oncol 1996 -V.63 -N.3 -P.201−8
- Coppin CM et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. // J Clin Oncol 1996 -N. 14 -P.2901−07
- Chen WC et al. Concurrent Cisplatin, 5-Fluorouracil, Leucovorin, and radiotherapy for invasive bladder cancer. // Int J Radiat Oncol Biol Phys 2003 — V.56 — N.3 — P.726−33
- Cox DR. The analysis of exponentially distributed life-times with two types of failures. // Journal of the Royal Statistical Society 1959 -№ 21 — P.411−21
- Cox DR. Some applications of exponential ordered scores.// Journal of the Royal Statistical Society 1964 — № 26 — P. 103−110
- Dalbagni G et al. Cystectomy for bladder cancer: a contemporary series // J Urol-2001 -165-P. 1111−6
- Dunst J et al. Organ sparing treatment of advanced bladder cancer: a 10 year experience. // Int J Radiat Oncol Biol Phys 1994 — V.30 — P.261−66
- Durdux C et al. Radiotherapy and chemotherapy in infiltrating bladder tumors. // Rev Prat 1997 — V.47 — N.4 -P.392−5
- Freeman JA et al. Partial cystectomy and radical cystectomy. // Urol Oncol -1997-P.302−17
- Fu KK Biological Basis for the interaction of chemotherapentic agents and radiation therapy // Cancer 1985 — V.55 — N 9
- Geard CR., et al. Taxol and radiation // J Natl Cancer Inst Monogr 1993 -N.15 — P.89−94
- Ghoneim MA et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases // J Urol 1997 — 158 — P. 393−9
- Grossman HB et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. // N Engl J Med 2003 -V.349-P.859−66
- Gospodarowicz MK et al. Bladder cancer long term follow-up results of patients treated with radical radiation. // J Clin Oncol 1991 -N.3 — P. 155−61
- Gschwend JE et al. Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. // Eur Urol 2000 — N.38 -P.121−130
- Henningsohn L et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. // Radiotherapy and Oncology 2002 — N.62 — P.215−25
- Herr HW et al. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. // J Clin Oncol 1998 — N 16. -P. 1298−301
- Herr HW et al. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome.//J Clin Oncol-2001 V.19-N.1 -P.89−93
- Herr HW et al. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. // J Clin Oncol 1994 — V. 12 — N.5 — P.975−980
- Horwich A et al. Conservative treatment of bladder cancer. // Clin Oncol -2004 V. 16 — P. 163−65
- Hussain M et al. Combined Cisplatin, 5-Fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. // J Urol 2001 — V.165 — N. l — P.56−60
- Housset M et al. Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: a prospective study. // J Clin Oncol — 1993 Y. l 1 -P.2150−2157
- International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastin chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. // Lancet 1999 — V.354 — P.533−540
- Kachnic LA et al. Bladder preservation by combined modality therapy for invasive bladder cancer. // J Clin Oncol 1997 — N. 15 — P. 1022−1029
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. // Journal of the American Statistical Association 1958 — N.53 — P.457−481
- Lebret T et al. Study of survival after cystectomy for bladder cancer. Report of 504 cases // Prog Urol 2000 — V. 10 — N.4 — P.553−60
- Malmstrom P-U et al. Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial 1. // J Urol 1996 — V. 155 — P. 1903−06
- Martinez-Pineiro JA et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomised phase 111 study. // J Urol 1995 — V. 153 — P.964−73
- Matos T et al. Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). // Int J Radiat Oncol Biol Phys 2000 — V.46 — N.2 — P.403−409
- McCaffrey JA et al. Combined-modality therapy for bladder cancer. // Oncology 1997 — V. 11 (Suppl 9) — P. 18−26
- Mel JR et al. Paclitaxel and cisplatin as neoadjuvant chemotherapy in locally advanced bladder cancer. // ASCO 2001
- Millikan R et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versuscystectomy with both preoperative and postoperative M-VAC. // J Clin Oncol -2001 V. 19 — P.4005−13
- Moonen L et al. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. // Int J Rad Oncol Biol Phis 1998 — V.42 — N.3 -P.525−30
- Nichols RC et al. Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination. // Int J Cancer 2000 — V.90 — N.5 — P.281 -6
- Novick AC et al. Partial cystectomy in the treatment of primary and secondary carcinoma of the bladder. // J Urol 1976 — V. l 16 — P.570l.Ozols RF et al. Cancer chemotherapy and biological response modifiers. // Annual 11. Elsevier 1990 — P.602−630
- Pagano F et al. Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. // J Urol 1991 — V. 145 — P.45−50
- Paz-Ares L et al. CMV front line chemotherapy in transitional bladder carcinoma. // Ann Oncol 1993 — V.4 — N.2 — P. 147−50
- Rivera I et al. Bladder-sparing treatment of invasive bladder cancer. // Cancer Control 2000 — N.4 — P.340−346
- Sangar VK et al. Chemoradiation with once-weekle gemcitabine for invasive bladder cancer. // Eur Urol 2003(Suppl 2) — abstr. 497
- Sauer R et al. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer. // Int J Rad Oncol Biol Phis 1998 — V.40 -N.l-P.121−127
- Takahashi A et al. Radical cystectomy for invasive bladder cancer: results of multiinstitutional pooled analysis. // Jpn J Clin Oncol 2004 — V.34 — N. l -P.14−19
- Tester W et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. // J Clin Oncol 1996 — V. 14 — P. 119−26
- Thomas DJ et al. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up. // Brit J Urol Int 1999 — V.83 — P.432−437,
- Tubiana M et al. The integrated alternating regimen // Cancer 1985 — V.55 -N.9 — P.
- Utz DC et al. A clinicopathologic evaluation of partial cystectomy for carcinoma of the urinary bladder. // Cancer 1973 — V.32 — P. 1075
- Van der Steen-Banasik EM et al. Saving bladders with brachitherapy: implantation technique and results. // Int J Rad Oncol Biol Phis 2002 — V.53 -N.3 — P.622−629
- Van Poppel H et al. Brachitherapy with iridium-192 for bladder cancer. // Eur Urol 2000 — V.37 — P.605−608
- Vieweg K et al. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. // J Urol 1999 — 161 — P. 449−54
- Vogelzang NJ et al. Methotrexat, vinblastin, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. // J Urol 1993 — V. 149 — P.753−57
- Wallace DMA, Raghavan D et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. // Br J Urol 1991 — V.67 -P.608−15
- Zietman AL et al. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy. // Ann Med 2000 — V.32 -N.l — P.34−42